NCT05309915

A Study of STP707 Administered by IV in Healthy Subjects

A Phase 1, Single-Center, Randomized, Dose-Escalation, Sequential Cohort Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Dose of STP707 Administered Intravenously in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Sirnaomics · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Single center study, randomized, to evaluate safety, tolerability, PK of single ascending dose of STP707 when administered by IV infusion in healthy subjects.

Detailed description

The study includes a screening period, admission, treatment period and follow up period. Four doses will be evaluated in 4 cohorts with up to 10 subjects per cohort. Each individual will receive a single dose of STP707 or placebo.

Conditions

• Healthy Subjects

Interventions

Type	Name	Description
DRUG	STP707	STP707 Powder for Injection, contains 2 (siRNA) and (HKP+H) delivery system.

Timeline

• Start date: 2022-02-28
• Primary completion: 2022-08-30
• Completion: 2022-08-30
• First posted: 2022-04-04
• Last updated: 2024-03-18

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study